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Spondylodiscitis Associated with Recurrent Serratia Bacteremia
Due to a Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Case Report
Nuno Marques, Rosa Sá, Filomena Coelho, Saraiva da Cunha and A. Meliço-Silvestre
Infectious Diseases Departemtn, University of Coimbra; Coimbra, Portugal
We report a case of spondylodiscitis caused by multiresistant Serratia marcescens in a cirrhotic patient who had
several Serratia bacteremias after the placement of a transjugular intrahepatic portosystemic shunt (TIPS) device.
We concluded that an endovascular stent that can not be removed makes management of recurrent bacteremia
difficult. Furthermore, back pain due to bacteremia is indicative of spondylodiscitis. Serratia marcescens can be an
aggressive pathogen, causing spinal infection.
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Case Report
A 59-year-old Caucasian man had liver cirrhosis due to
alcohol abuse, which was complicated by portal hypertension
and esophageal varices. Because of acute upper
gastroenterological bleeding and transesophageal sclerosis
of varices, he underwent a transjugular intrahepatic
portosystemic shunt (TIPS) procedure performed at our
hospital. As he also had aspiration pneumonia, intravenous
antibiotic therapy with cefoxitin was done for four days. There
was gradual clinical improvement, and he was transferred to
his local hospital. However, blood cultures collected seven
days after TIPS revealed Serratia marcescens, which was only
susceptible to cefotaxime, ceftazidime and imipenem. Imipenem
was administered during seven days.
Three weeks after TIPS, the patient developed low-back
pain and fever (38.5ºC), without neurological involvement.
Lumbar radiography and computed tomography were
compatible with degenerative processes. The blood cultures
showed S. marcescens, which was susceptible to the
previously-mentioned antibiotics. Imipenem was reinitiated
for another seven days. Ten weeks after TIPS, he was
transferred to our department to determine the source of the
bacteremia. On admission, he complained of worsening low-
back pain, and he was febrile (38.3ºC). Laboratory blood
examination showed C-reactive protein to be 5.7 mg/dL (normal
values: 0.0-0.5 mg/dL), erythrocyte sedimentation rate 48 mm/
hr and white blood cell counts 8.8x109/L, with 75% segmented
neutrophils. The blood cultures revealed S. marcescens, which
was only susceptible to imipenem.
A gallium-67 citrate scan revealed an increased uptake at
D9-D11, probably due to spondylodiscitis, which was
confirmed by bone scanning with technetium-99m and
magnetic resonance imaging. He had no central line devices,
and the urine cultures were negative. The abdominal Doppler
ultrasound showed a TIPS stent with a normal-direction blood
flow. Abdominal ultrasound and chest X-rays, as well as
transthoracic echocardiography, were normal.
The patient could only walk with the aid of a thoracolumbar
brace, and imipenem was administered from the 10th until the
45th week after TIPS, with substantial clinical improvement
and discrete imaging symptom stabilization. His next
presentation was 48 weeks after TIPS, with a recrudescence
of fever, despite 36 weeks of antibiotic therapy. He had a
satisfactory clinical condition, no longer wore a lumbar
support, and the lab data (ESR, CRP, WBC) showed a good
response. However, S. marcescens was again isolated from
the blood cultures, and it had the same antibiotic-resistance
pattern. Although Doppler ultrasound showed the TIPS device
to have no thrombus or vegetations, we considered the
hypothesis of TIPS infection or colonization by Serratia sp.,
and we established a plan to continue anti-Serratia treatment,
possibly ab aeterno with imipenem or ertapenem. The patient
received antibiotic therapy with imipenem for a further 50
weeks. At that time (98 weeks after TIPS) we decided to
suspend antibiotic treatment, as he maintained radiological
stabilization of the infectious process. Twenty-six weeks after
being discharged without antibiotic therapy, he had no fever
or other evidence of bacteremia, and he had no back-pain
complaints. The patient was able to go about his daily activities
without any disability. Radiography and clinical appearance
was suggestive of vertebral bone fusion between D9-D10 and
D10-D11. He had no further variceal bleeding.
Discussion
Serratia marcescens is an aerobic Gram-negative bacillus
that belongs to the family Enterobacteriaceae; when it was
discovered, in the nineteenth century it was believed to be a
microorganism with low virulence [1]. However, since the
1960s, it is considered to be an opportunistic human pathogen.
It tends to colonize the respiratory and urinary tracts of adults
in health-care institutions and has been associated with
outbreaks of nosocomial infections. Among all nosocomial
bacteremias, 1.2 to 1.4% are caused by Serratia species [2-4].
Central nervous infection caused by S. marcescens can occur,
particularly in neonates with prior sepsis or after a
neurosurgical procedure or lumbar puncture [5]. In drug
addicts, it can cause endocarditis (often left-sided) and
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osteomyelitis [6,7]. Nevertheless, Serratia rarely affects the
bones and joints [8]. Patients with nosocomial infections,
diabetes mellitus, renal failure, who have a debilitated immune
status, or have traumatic open wounds, as well as the elderly
and drug addicts, are the most susceptible to Serratia
infections [8,9]. These infections are associated with high
mortality (25%-52%), especially when they progress to
bacteremia [9-11].
Serratia spp. can survive under hostile conditions,
including in disinfectant solutions, which can become the
source for outbreaks; in addition they can spread within or
among health care institutions on the hands of staff [1]. The
source of most infections of the intervertebral disc is the blood;
though it can also occur postoperatively. There are relatively
few cases of post-operative spinal infection due to Serratia
(two cases after elective lumbar spine surgery, one case after
anterior cervical discectomy and fusion and another case after
post-lumbar vertebroplasty) [9,12,13]. We also found two cases
of Serratia osteomyelitis in recently-fractured vertebra [14].
Our patient was profoundly debilitated on admission at
our hospital, and he had a respiratory tract infection. Later, he
suffered from spondylodiscitis due to hematogenous
dissemination of S. marcescens following TIPS device
placement. Besides hospitalization he had other risk factors
for acquiring Serratia infection, including prior antibiotic
therapy, chronic-liver disease and an endovascular device.
The definition of a TIPS device infection or endotipsitis is
controversial; alternatives include sustained bacteremia in a
patient with a TIPS device, with or without thrombus, plus
either no other identifiable infective focus or an identifiable
infective focus that is not considered to be the source of the
bacteremia after intense investigation of endotipsitis
characterization [15]. Although there was an identifiable
infective focus (spondylodiscitis) for the bacteremia, the
clinical outcome and the recurrent Serratia bacteremias lead
us to believe that the source of the infection was colonization
of the TIPS device, even though there were no signs of
infection in the Doppler ultrasound exam. If the bacteremias
provoke the spondylodiscitis process, we would expect
worsening back pain and image symptoms each time they
reoccur, which has not always been the case. Recurrent
bacteremia is characterized by isolation of the same organism
from the blood cultures after at least five days of appropriate
antibiotic therapy [4]. Infection of a TIPS devices is rare; the
estimated overall infection rate varies from 1.7 - 5.1% of the
procedures performed; infection can occur several months or
years after stent placement [15,16].
Removal of the intravascular device is the best recourse
for management of recurrent bacteremias, but this approach
is not achievable in some circumstances; this was the case for
our patient, because TIPS surgical removal was not possible
without liver transplantation. Serratia marcescens is resistant
to ampicillin, macrolides and first-generation cephalosporins;
treatment usually includes an antipseudomonal beta-lactam
and an aminoglycoside [1,17]. Most strains are susceptible to
quinolones as well. Monotherapy with a beta-lactam is not
advised because resistant mutants can be selected.
Furthermore, cross-resistance to aminoglycosides can
accompany beta-lactam resistance [4]. Multiresistant strains
have been emerging during the last decades; therefore
treatment should be based on susceptibility tests. In our case,
imipenem was the first treatment choice, and it rapidly became
the only option. Cefoxitin is known to be a potent beta-
lactamase inducer; previous utilization can provoke cross
resistance [4]. The patient was treated with imipenem for long
periods, including 36 continuous weeks, followed by another
50 continuous weeks. Since the resistance pattern of this
Serratia infection did not allow oral treatment, our patient
had to remain hospitalized during long periods or had to go
the hospital daily for intravenous antibiotic therapy.
In one of the largest published series of Serratia bacteremia
(122 episodes during a 10-year period), imipenem gave the lowest
resistance rate (0.87%), followed by amikacin (19.4%) and
cefepime (22.6%) [4]. Nonetheless, beta-lactamase-mediated
carbapenem resistance has been reported for many Gram-
negative organisms, including S. marcescens [18,19].
Even though there is no consensus concerning the
duration of antibiotic therapy in a spondylodiscitis process,
we think that antimicrobial suppression should be continued
for a long period.
We do not know if the lengthy antibiotic treatment period
was sufficient to resolve the spondylodiscitis process or if it
resulted in sterilization of a TIPS-device colonization process.
However, we conclude that early diagnosis and aggressive
treatment of spondylodiscitis are essential.
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